These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 29089726)

  • 21. Idarucizumab for Reversal of Dabigatran: Single-Center Real-World Experience.
    Sheikh-Taha M
    Am J Cardiovasc Drugs; 2019 Feb; 19(1):59-64. PubMed ID: 30203330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Idarucizumab administration in emergency situations: the Munich Registry of Reversal of Pradaxa® in clinical routine (MR REPAIR).
    Küpper C; Feil K; Klein M; Feuerecker R; Lücking M; Thanbichler F; Dietrich D; Zerkaulen I; Jandl M; Marziniak M; Poppert H; Wunderlich S; Topka H; Dieterich M; Kellert L
    J Neurol; 2019 Nov; 266(11):2807-2811. PubMed ID: 31375990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Emerg Med; 2016 Nov; 34(11S):26-32. PubMed ID: 27707528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Practical considerations on anticoagulation reversal: spotlight on the reversal of dabigatran.
    Giannandrea D; Mengoni A; Carluccio E; Ambrosio G
    Vasc Health Risk Manag; 2019; 15():139-142. PubMed ID: 31213821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two Dabigatran Fast Reversals in a 4-month Period - a Case Report.
    Fagundes V; Mesquita M
    Eur J Case Rep Intern Med; 2019; 6(12):001311. PubMed ID: 31893202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran.
    Simon A; Domanovits H; Ay C; Sengoelge G; Levy JH; Spiel AO
    J Thromb Haemost; 2017 Jul; 15(7):1317-1321. PubMed ID: 28426914
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases.
    Vosko MR; Bocksrucker C; Drwiła R; Dulíček P; Hauer T; Mutzenbach J; Schlimp CJ; Špinler D; Wolf T; Zugwitz D
    J Thromb Thrombolysis; 2017 Apr; 43(3):306-317. PubMed ID: 28210988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose requirements for idarucizumab reversal of dabigatran in a lethal porcine trauma model with continuous bleeding.
    Honickel M; Spronk HM; Rossaint R; Stoppe C; van Ryn J; Ten Cate H; Grottke O
    Thromb Haemost; 2017 Jun; 117(7):1370-1378. PubMed ID: 28424818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incomplete responses to the recommended dose of idarucizumab: a systematic review and pharmacokinetic analysis.
    Athavale A; Jamshidi N; Roberts DM
    Clin Toxicol (Phila); 2020 Aug; 58(8):789-800. PubMed ID: 32267185
    [No Abstract]   [Full Text] [Related]  

  • 30. Reversal of Dabigatran with Idarucizumab.
    Sodha NR; Sellke FW
    Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):889-93. PubMed ID: 27362456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Whole Blood Point-of-Care Testing for Incomplete Reversal With Idarucizumab in Supratherapeutic Dabigatran.
    Takeshita S; Tanaka KA; Sawa T; Sanda M; Mizobe T; Ogawa S
    Anesth Analg; 2020 Feb; 130(2):535-541. PubMed ID: 31490820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute reversal of dabigatran with Idarucizumab for intravenous thrombolysis as acute stroke treatment.
    Meyer D; Chu F; Derry K; Hailey L
    J Clin Neurosci; 2019 Jan; 59():355-357. PubMed ID: 30309801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incomplete dabigatran reversal with idarucizumab.
    Steele AP; Lee JA; Dager WE
    Clin Toxicol (Phila); 2018 Mar; 56(3):216-218. PubMed ID: 28704111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Idarucizumab (Praxbind
    Kalmanovich E; Battistella P; Rouviere P; Albat B; Frapier JM; Demaria R; Huet F; Agullo A; Mourad M; Colson P; Leclercq F; Gaudard P; Roubille F
    Future Sci OA; 2021 Feb; 7(4):FSO689. PubMed ID: 33815827
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.
    Honickel M; Treutler S; van Ryn J; Tillmann S; Rossaint R; Grottke O
    Thromb Haemost; 2015 Apr; 113(4):728-40. PubMed ID: 25567155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Idarucizumab (Praxbind) for Dabigatran (Pradaxa) Anticoagulant Reversal.
    Jarrett JB; Gimbar RP
    Am Fam Physician; 2017 Jun; 95(12):798-800. PubMed ID: 28671421
    [No Abstract]   [Full Text] [Related]  

  • 37. Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study.
    Pollack CV; Bernstein R; Dubiel R; Reilly P; Gruenenfelder F; Huisman MV; Kam CW; Kleine E; Levy JH; Sellke FW; Steiner T; Ustyugova A; Weitz JI
    J Med Econ; 2017 May; 20(5):435-442. PubMed ID: 27981865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Idarucizumab for the treatment of hemorrhage and dabigatran reversal in patients requiring urgent surgery or procedures.
    Vornicu O; Larock AS; Dincq AS; Douxfils J; Dogné JM; Mullier F; Lessire S
    Expert Opin Biol Ther; 2017 Oct; 17(10):1275-1296. PubMed ID: 28728489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis.
    Hutcherson TC; Cieri-Hutcherson NE; Bhatt R
    P T; 2017 Nov; 42(11):692-698. PubMed ID: 29089725
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic Thrombolysis in Acute Ischemic Stroke after Dabigatran Etexilate Reversal with Idarucizumab-A Case Report.
    Tireli D; He J; Nordling MM; Wienecke T
    J Stroke Cerebrovasc Dis; 2017 Jul; 26(7):e123-e125. PubMed ID: 28479184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.